Peregrine Capital Management LLC Purchases 26,559 Shares of Soleno Therapeutics, Inc. $SLNO

Key Points

• Peregrine Capital Management LLC boosted its stake in Soleno by 28.6%, purchasing 26,559 shares to hold 119,564 shares (about 0.22% ownership) valued at roughly $5.54 million at quarter‑end.
• Multiple national plaintiff firms are soliciting a proposed securities class action alleging post‑launch safety and launch disruptions for VYKAT XR, and a separate shareholder probe into the Neurocrine transaction adds potential litigation and deal uncertainty.
• Shares traded near $52.83 (1‑year range $29.43–$90.32) with a $2.73B market cap; analysts' consensus is Hold with an average price target of $76.67 after several downgrades.

Peregrine Capital Management LLC boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 28.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 119,564 shares of the company's stock after purchasing an additional 26,559 shares during the period. Peregrine Capital Management LLC owned about 0.22% of Soleno Therapeutics worth $5,536,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in SLNO. Raymond James Financial Inc. bought a new position in Soleno Therapeutics during the 2nd quarter valued at about $25,000. Danske Bank A S bought a new position in Soleno Therapeutics during the 3rd quarter valued at about $27,000. Aster Capital Management DIFC Ltd bought a new position in Soleno Therapeutics during the 3rd quarter valued at about $37,000. Quarry LP bought a new position in Soleno Therapeutics during the 3rd quarter valued at about $47,000. Finally, Quantbot Technologies LP bought a new position in Soleno Therapeutics during the 3rd quarter valued at about $67,000. 97.42% of the stock is owned by institutional investors.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: Multiple national plaintiff firms (Rosen, Hagens Berman, Faruqi & Faruqi, Bernstein Liebhard, Glancy Prongay Wolke & Rotter, Levi & Korsinsky, SueWallSt, Schall, Bronstein Gewirtz & Grossman and others) are notifying Soleno investors of a proposed securities class action and urging losses to be submitted before the May 5, 2026 lead‑plaintiff deadline. These coordinated solicitations typically signal potential material litigation exposure and can increase stock volatility and legal costs. Read More.
• Negative Sentiment: Several notices allege investor harm tied to Soleno’s commercialization of VYKAT XR (DCCR) and claim the company concealed post‑launch safety or launch disruptions; such allegations can lead to damages claims, management distraction, and reputational risk even before any merits are adjudicated. Read More.
• Negative Sentiment: The Ademi Firm is separately investigating whether Soleno’s recently announced transaction with Neurocrine was fair to public shareholders, raising potential fiduciary‑duty claims that could complicate or delay the deal and increase uncertainty for investors. Read More.

Soleno Therapeutics Trading Up 0.2%

Shares of NASDAQ SLNO opened at $52.83 on Friday. Soleno Therapeutics, Inc. has a 1-year low of $29.43 and a 1-year high of $90.32. The company has a market cap of $2.73 billion, a PE ratio of 229.71 and a beta of -2.81. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $41.00 and a two-hundred day moving average of $47.23.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. As a group, equities analysts expect that Soleno Therapeutics, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SLNO shares. TD Cowen downgraded shares of Soleno Therapeutics from a "buy" rating to a "hold" rating and cut their price target for the company from $85.00 to $53.00 in a report on Tuesday, April 7th. Wells Fargo & Company set a $53.00 target price on shares of Soleno Therapeutics and gave the stock an "equal weight" rating in a research note on Friday, April 17th. Robert W. Baird downgraded shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research downgraded shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $76.67.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.